Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The prevalence of difficult-to-treat infections is increasing worldwide, despite regional variations in the etiological pathogens. This report provides an extensive overview of the use of antibiotics in Brazil and Mexico, with a special focus on complicated hospital-treated infections (HTIs) due to methicillin-resistant Staphylococcus aureus (MRSA) and gram-negative pathogens. Such multi-drug resistant pathogens are becoming increasingly life-threatening and burdensome to local healthcare economies, which are overflowing with generics from a broad range of antibiotic classes. However, governments are keen to regulate the use of antibiotics so that forthcoming multi-drug resistance can be restrained. Healthcare providers struggle to employ more effective and costly antibiotics that address complicated infections caused by resistant pathogens in these cost-constrained markets. Thus, novel antibiotics, such as Actavis/AstraZeneca’s Avycaz, The Medicines Company’s Carbavance, Tetraphase’s eravacycline, and Merck’s Zerbaxa, must overcome stringent clinical and reimbursement challenges.
This Emerging Markets Physician & Payer Forum surveys 101 infectious disease specialists, internal medicine physicians, and primary care physicians and interviews six payers in Brazil and Mexico, to explore how the antibiotic market space for HTIs is currently shaped and how it will evolve in these countries in the next two to three years. Interviewees were required to be influential in determining patient access to therapies for HTIs at the institutional or regional/national level, and they came from the following backgrounds:
Head of pharmaceutical assistance programs at São Paulo State, consultant for the São Paulo State Department of Health and the MoH; head of the Patient Safety Program at Ebserh for the MoH at several federal hospitals, member of the working group for the Pharmaceutical Assistance Qualification Program of the MoH (QUALIFAR-SUS); head of the nephrology department at a large university hospital at the Paraná State, professor at the same hospital, member of the drug standardization committee of the institution.
Mexico: Head of the Epidemiology and Preventive Medicine Program at ISSSTE, including the Epidemiological Surveillance of Nosocomial Infections Program, member of the Hospital Epidemiological Surveillance network (RHoVE); infectious diseases specialist at a major Ministry of Health hospital, member of the infectious diseases committee and transplant committees, member of the RHoVE, private practitioner; infectious disease specialist, head of department and member of the epidemiological surveillance committee at a major IMSS hospital.
Already a Client? Log in to access this report.